The latest announcement is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc reported record financial results for 2024, with revenue increasing by 11.9% to £62.7 million and EBITDA rising by 25.9% to £16.4 million. The company has made significant strategic progress, including the signing of key contracts and the acquisition of two Clinical Research Units from CRS, which are expected to enhance earnings and expand revenue streams. The company is focusing on integrating these new assets and maintaining its growth trajectory, with a medium-term revenue target of £100 million by 2028. The announcement also noted the departure of Chair Cathal Friel, who played a pivotal role in the company’s transformation.
More about Open Orphan Plc
hVIVO plc is a full-service Contract Research Organisation (CRO) specializing in human challenge clinical trials. The company is recognized as a world leader in this niche, providing services that accelerate drug development and innovation in the biopharmaceutical industry.
YTD Price Performance: -27.80%
Average Trading Volume: 3,219,357
Technical Sentiment Signal: Strong Buy
Current Market Cap: £98.21M
For a thorough assessment of HVO stock, go to TipRanks’ Stock Analysis page.